Charles River Laboratories International (CRL) Receivables (2009 - 2025)

Charles River Laboratories International's Receivables history runs 17 years deep, the most recent figure standing at $708.9 million for Q4 2025.

• In Q4 2025, Receivables fell 4.11% year-over-year to $708.9 million; the TTM figure through Dec 2025 stood at $708.9 million (down 4.11% YoY), while the FY2025 annual figure was $708.9 million, down 4.11% from the prior year.
• Receivables for Q4 2025 stood at $708.9 million, down from $734.5 million in the prior quarter.
• The five-year high for Receivables was $812.4 million in Q1 2024, with the low at $610.6 million in Q1 2021.
• The 5-year median for Receivables is $759.4 million (2024), against an average of $743.9 million.
• The sharpest annual moves came in 2021 and 2024: Receivables advanced 21.39% in 2021, then retreated 8.3% in 2024.
• Charles River Laboratories International's Receivables stood at $650.4 million in 2021, then climbed by 17.42% to $763.7 million in 2022, then grew by 5.56% to $806.1 million in 2023, then declined by 8.3% to $739.2 million in 2024, then decreased by 4.11% to $708.9 million in 2025.
• Business Quant data shows CRL's Receivables at $708.9 million in Q4 2025, $734.5 million in Q3 2025, and $780.4 million in Q2 2025.